Resources for students such as educational tools covering a variety of managed care topics and information on professional opportunities (internships, APPEs, fellowships and residencies) related to managed care pharmacy.
In the latest episode of Worth a Shot, Adam Colborn, JD, AMCP VP of government affairs, warns that ongoing disruption to the Advisory Committee on Immunization Practices (ACIP) process threatens vaccine access, particularly for low-income children and other vulnerable populations.
Mitzi Wasik, PharmD, MBA, BCPS, the senior vice president for practice advancement and member experience at AMCP, underscored some potential benefits of AI in core managed care areas such as medication adherence.
On Sept. 15, the House E&C Health Subcommittee held a hearing on H.R. 3164.
In this video, Christina, an artist, educator, and self-described "accidental advocate," shares her experience living with a desmoid tumor, a rare, locally invasive soft tissue tumor that forms in the body's connective tissue and is also known as aggressive fibromatosis or desmoid-type fibromatosis. She describes the uncertainty of her initial diagnosis, the multiple treatments that did not work, and finding a therapy that has helped keep her tumor stable.
As psychedelic-assisted therapies move closer to potential use in treating treatment-resistant depression (TRD), health plans, pharmacy benefit managers, and other managed care stakeholders are beginning to evaluate how these therapies could fit within existing coverage, reimbursement, and care delivery models. A new Journal of Managed Care + Specialty Pharmacy (JMCP) supplement from AMCP Market Insights provides a roadmap for many of the questions payers may face as innovative therapies enter the depression treatment landscape.
AMCP’s comments focus on provisions in the Proposed Rule that affect prescription drug payment and access to clinically appropriate therapies. AMCP has an interest in ensuring that Medicare payment and coverage policies promote transparency, control prices, preserve beneficiary access, and avoid fragmented incentives across care settings and benefit designs. AMCP encourages CMS to provide clear methodological explanations and monitor effects on beneficiary access and provider behavior.
On Aug. 28, AMCP responded to Senate HELP Chairman Bill Cassidy's 340B reform proposal.
AMCP supports efforts to make prescription medications more affordable for Medicare beneficiaries. At the same time, implementation of the Medicare Drug Price Negotiation Program (Negotiation Program) should preserve the evidence-based formulary management, utilization management, market competition, and clinical decision-making processes fundamental to managed care pharmacy.
The No Surprises Act Enforcement Act would increase insurer penalties up to $10,000 per surprise billing violation.
